

#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### 1. Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

## 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

### 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

### 5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### **Definitions.**

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes Pending: The patent has been filed but not issued Issued: The patent has been issued by the agency Licensed: The patent has been licensed to an entity, whether earning royalties or not Royalties: Funds are coming in to you or your institution due to your patent



| Section 1.                              |                           |                               |                      |   |
|---|---------------------------|-------------------------------|----------------------|---|
| Section 1.                              | Identifying Inform        | nation                        |                      |   |
| 1. Given Name (Fir<br>Jennifer          | rst Name)                 | 2. Surname (Last Name)<br>Lue |                      | 3. Date<br>05-August-2020               |
| 4. Are you the corr                     | responding author?        | ✓ Yes No                      |                      |   |
| 5. Manuscript Title<br>Targeting Pathog |                           | Narginal Zone Lymphoma: Fror  | n Concepts And Beyon | nd                                      |
| 6. Manuscript Ider<br>AOL-20-20         | ntifying Number (if you k | now it)                       |                      |   |
| Section 2.                              | The Work Under C          | onsideration for Publication  | on                   |   |
| Did you or your ins                     | I                         |                               |                      | mmercial, private foundation, etc.) for |

Are there any relevant conflicts of interest? Yes V No

| Are there any relevant connicts of interest? | res | ✓ |
|--|-----|---|
|  |     |   |

# Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

| Are there any relevant conflicts of interest? |                                       | No |
|---|---------------------------------------|----|
| Are there any relevant connicts of interest:  | I I I I I I I I I I I I I I I I I I I |    |

If yes, please fill out the appropriate information below.

| Name of Entity        | Grant?       | Personal<br>Fees? | Non-Financial<br>Support? | Other?       | Comments                                       |  |
|-----------------------|--------------|-------------------|---------------------------|--------------|--|--|
| Kymera Therapeutics   | $\checkmark$ |                   |                           |              | Research support and scientific advisory board |  |
| Astex Pharmaceuticals |              |                   |                           | $\checkmark$ | Scientific Advisory Board                      |  |
| AstraZeneca           |              |                   |                           | $\checkmark$ | Speakers' Bureau                               |  |
| Kura Oncology         |              |                   |                           | $\checkmark$ | Scientific Advisory Board                      |  |
| Daiichi Sankyo        |              |                   |                           | $\checkmark$ | Consulting                                     |  |



## Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes 🖌 No

## Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes, the following relationships/conditions/circumstances are present (explain below):

✓ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

## Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Lue reports grants and other from Kymera Therapeutics , other from Astex Pharmaceuticals, other from AstraZeneca, other from Kura Oncology , other from Daiichi Sankyo , outside the submitted work; .

#### **Evaluation and Feedback**

Please visit <u>http://www.icmje.org/cgi-bin/feedback</u> to provide feedback on your experience with completing this form.



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### 1. Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

## 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

### 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

### 5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

patent

#### **Definitions.**

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes Pending: The patent has been filed but not issued Issued: The patent has been issued by the agency Licensed: The patent has been licensed to an entity, whether earning royalties or not Royalties: Funds are coming in to you or your institution due to your



| Contion 1           |                                  |                              |  |
|---------------------|----------------------------------|------------------------------|--|
| Section 1.          | Identifying Inform               | nation                       |  |
|                     |                                  |                              |  |
| 1. Given Name (Fir  | st Name)                         | 2. Surname (Last Name)       | 3. Date  |
| Owen A.             |                                  | O'Connor                     | 11-August-2020   |
|                     |                                  |                              |  |
| 4. Are you the corr | esponding author?                | Yes 🖌 No                     | Corresponding Author's Name  |
|                     |                                  |                              | Lue and Bertoni  |
| 5. Manuscript Title |                                  |                              |  |
|                     |                                  | Arginal Zone Lymphoma        | : From Concepts And Beyond   |
| Targetting Fattio   |                                  |                              |  |
| 6. Manuscript Ider  | itifying Number (if you kr       | now it)                      |  |
| AOL-20-20           |                                  | ,                            |  |
|                     |                                  |                              |  |
|                     |                                  |                              |  |
|                     |                                  |                              |  |
| Section 2.          | The Work Under C                 | onsideration for Publ        | ication  |
|                     | The Work Onder C                 | onsideration for rush        |  |
| Did you or your ins | titution <b>at any time</b> rece | ive payment or services from | n a third party (government, commercial, private foundation, etc.) for |

any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)? Are there any relevant conflicts of interest?

## Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were **present during the 36 months prior to publication**.

| Are there any relevant conflicts of interest? | Ves | No |
|---|-----|----|
| Are there any relevant connicts of interest:  | 162 |    |

If yes, please fill out the appropriate information below.

| Name of Entity               | Grant? | Personal<br>Fees <b>?</b> | Non-Financial<br>Support? | Other?       | Comments                             |
|------------------------------|--------|---------------------------|---------------------------|--------------|--------------------------------------|
| Celgene/Bristol Myers Squibb |        |                           |                           | $\checkmark$ | consulting fees and research support |
| Kymera                       |        |                           |                           | $\checkmark$ | consulting fees and equity stake     |
| TG Therapeutics              |        | $\checkmark$              |                           | $\checkmark$ | salary and equity stake              |
| Mundipharma                  |        |                           |                           | $\checkmark$ | consulting fees and research support |
| Merck                        |        |                           |                           | $\checkmark$ | consulting fees and research support |
| Astec                        |        |                           |                           | $\checkmark$ | consulting fees and research support |
| Affimed                      |        |                           |                           | $\checkmark$ | consulting fees and research support |
| Trillium                     |        |                           |                           | $\checkmark$ | consulting fees and research support |



| Section 4.       | Intellectual Property Patents & Copyrights  |
|------------------|---|
| Do you have an   | y patents, whether planned, pending or issued, broadly relevant to the work? 🗌 Yes 🖌 No   |
| Section 5.       |   |
| Section 5.       | Relationships not covered above   |
|                  | relationships or activities that readers could perceive to have influenced, or that give the appearance of<br>encing, what you wrote in the submitted work? |
| Yes, the follo   | owing relationships/conditions/circumstances are present (explain below):   |
| ✓ No other rel   | ationships/conditions/circumstances that present a potential conflict of interest   |
| At the time of m | nanuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements.  |

On occasion, journals may ask authors to disclose further information about reported relationships.

## Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. O'Connor reports other from Celgene/Bristol Myers Squibb, other from Kymera, personal fees and other from TG Therapeutics, other from Mundipharma, other from Merck, other from Astec, other from Affimed, other from Trillium, outside the submitted work; .

#### **Evaluation and Feedback**

Please visit <u>http://www.icmje.org/cgi-bin/feedback</u> to provide feedback on your experience with completing this form.



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### 1. Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

## 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

### 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

### 5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

patent

#### **Definitions.**

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes Pending: The patent has been filed but not issued Issued: The patent has been issued by the agency Licensed: The patent has been licensed to an entity, whether earning royalties or not Royalties: Funds are coming in to you or your institution due to your



| Section 1.                               | Identifying Infor             | mation                              |                          |   |
|--|-------------------------------|-------------------------------------|--------------------------|---|
| 1. Given Name (First<br>Francesco        | Name)                         | 2. Surname (Last Name)<br>Bertoni   |                          | 3. Date<br>08-November-2020             |
| 4. Are you the corres                    | sponding author?              | ✓ Yes No                            |                          |   |
| 5. Manuscript Title<br>Targeting Pathoge | enic Mechanisms In            | Marginal Zone Lymphoma: Fron        | n Concepts And Beyon     | ıd                                      |
| 6. Manuscript Identi<br>AOL-20-20        | fying Number (if you l        | know it)                            |                          |   |
| Section 2.                               | he Work Under (               | Consideration for Publicatio        | on                       |   |
| Did you or your instit                   | tution <b>at any time</b> rec | eive payment or services from a thi | rd party (government, co | mmercial, private foundation, etc.) for |

any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)? √ No a: .... -+2 UV-. +h ۸ ~ ~

| Are there any relevant conflicts of interest? | Yes | √ |
|---|-----|---|
|   |     |   |

#### Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication.

| Are there any relevant conflicts of interest? |       | No |
|---|-------|----|
| Are there any relevant connicts of interest:  | v res |    |

If yes, please fill out the appropriate information below.

| Name of Entity    | Grant? | Personal<br>Fees? | Non-Financial<br>Support? | Other?       | Comments  |  |
|-------------------|--------|-------------------|---------------------------|--------------|---|--|
| Acerta            |        |                   |                           | $\checkmark$ | institutional research funds                    |  |
| ADC Therapeutics  |        |                   |                           | $\checkmark$ | institutional research funds                    |  |
| Bayer AG          |        |                   |                           | $\checkmark$ | institutional research funds                    |  |
| Cellestia         |        |                   |                           | $\checkmark$ | institutional research funds                    |  |
| CTI Life Sciences |        |                   |                           | $\checkmark$ | institutional research funds                    |  |
| EMD Serono        |        |                   |                           | $\checkmark$ | institutional research funds                    |  |
| Helsinn           |        |                   |                           | $\checkmark$ | institutional research funds, consultation fees |  |



| Name of Entity                   | Grant?       | Personal<br>Fees <b>?</b> | Non-Financial<br>Support? | Other?       | Comments   |  |
|----------------------------------|--------------|---------------------------|---------------------------|--------------|--|--|
| ImmunoGen                        |              |                           |                           | $\checkmark$ | institutional research funds                       |  |
| Menarini Ricerche                |              |                           |                           | $\checkmark$ | institutional research funds,<br>consultation fees |  |
| NEOMED Therapeutics 1            |              |                           |                           | $\checkmark$ | institutional research funds                       |  |
| Nordic Nanovector ASA            |              |                           |                           | $\checkmark$ | institutional research funds                       |  |
| Oncology Therapeutic Development |              |                           |                           | $\checkmark$ | institutional research funds                       |  |
| PIQUR Therapeutics AG            | $\checkmark$ |                           |                           |              | institutional research funds, travel<br>grant      |  |
| нтд                              |              |                           |                           | $\checkmark$ | expert statements                                  |  |
| Amgen                            | $\checkmark$ |                           |                           |              | travel grant                                       |  |
| Astra Zeneca                     | $\checkmark$ |                           |                           |              | travel grant                                       |  |
| Jazz Pharmaceuticals             | $\checkmark$ |                           |                           |              | travel grant                                       |  |

#### **Section 4.**

#### **Intellectual Property -- Patents & Copyrights**

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes 🖌 No

## Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

Yes, the following relationships/conditions/circumstances are present (explain below):

✓ No other relationships/conditions/circumstances that present a potential conflict of interest

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.



## Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Bertoni reports other from Acerta, other from ADC Therapeutics, other from Bayer AG, other from Cellestia, other from CTI Life Sciences, other from EMD Serono, other from Helsinn, other from ImmunoGen, other from Menarini Ricerche, other from NEOMED Therapeutics 1, other from Nordic Nanovector ASA, other from Oncology Therapeutic Development, grants and other from PIQUR Therapeutics AG, other from HTG, grants from Amgen, grants from Astra Zeneca, grants from Jazz Pharmaceuticals, outside the submitted work; .

#### **Evaluation and Feedback**

Please visit <u>http://www.icmje.org/cgi-bin/feedback</u> to provide feedback on your experience with completing this form.